ContributorsPublishersAdvertisers

Rinvoq Meets Primary Endpoints as Treatment for Active Ankylosing Spondylitis

pharmacytimes.com
 2021-10-11

Cover picture for the articleAbbVie announced positive top-line results from a phase 3 trial for the efficacy and safety of upadacitinib for individuals with the rheumatic disease. AbbVie has announced positive top-line results from a phase 3 clinical trial that evaluated the efficacy and safety of upadacitinib (Rinvoq) for individuals with active ankylosing spondylitis (AS)...

www.pharmacytimes.com

Comments / 0

Comments / 0